Form 8-K - Current report:
SEC Accession No. 0000950170-24-074860
Filing Date
2024-06-18
Accepted
2024-06-18 16:10:58
Documents
11
Period of Report
2024-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K pstx-20240617.htm   iXBRL 8-K 55974
  Complete submission text file 0000950170-24-074860.txt   173698

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240617.xsd EX-101.SCH 25968
14 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240617_htm.xml XML 4940
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 241051863
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)